Parkinson’s Foundation, Tag.bio partner to accelerate research, improve care for PD

The Parkinson’s Foundation and data analytics platform Tag.bio have announced a partnership to advance research into the causes and treatment of Parkinson’s disease.

According to a release issued by Tag.bio, the collaboration will enable researchers across each organization to securely analyze and share data combining clinical and genomics data sets, with the goal of improving PD care by accelerating and supporting research to advance improved treatments and personalized medicine.

“With this partnership, for the first time, researchers across organizations will be able to investigate harmonized, clinical and genomics data products using the most advanced data mesh framework, to help advance research into the causes and treatment of Parkinson’s disease,” Tom Covington, CEO of Tag.bio, stated in the release.

The Parkinson’s Foundation plans to support the research community by linking multiple deidentified datasets from PD GENEration: Mapping the Future of Parkinson’s Disease, a national initiative that provides genetic testing and counseling for seven PD-related genes to individuals with a confirmed PD diagnosis at no cost, the release stated, which will help individuals diagnosed with PD and their physicians identify whether they qualify for enrollment in certain clinical trials.

“By providing the research community with tools and a library of data, we hope to make strides in advancing Parkinson’s research, spark discoveries in treatment and improve the overall care of people living with the disease,” Parkinson’s Foundation Chief Scientific Officer James Beck, PhD, said in the release.